Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.59 – $3.13
40% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $157.0K | $148.0K | $115.0K | $148.0K | $205.0K | $405.0K | $212.0K | $161.0K |
| Gross profit | −$157.0K | −$148.0K | −$115.0K | −$148.0K | −$205.0K | −$405.0K | −$212.0K | −$161.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.8M | $7.6M | $10.5M | $10.0M | $12.3M | $14.3M | $8.3M | $0 |
| Operating income | −$10.0M | −$11.1M | −$14.1M | −$13.9M | −$17.3M | −$20.0M | −$19.3M | −$25.9M |
| EBITDA | −$9.8M | −$10.4M | −$14.0M | −$13.7M | −$17.0M | −$18.7M | −$17.6M | −$9.3M |
| Net income | −$9.8M | −$10.6M | −$13.8M | −$13.8M | −$17.2M | −$19.1M | −$17.6M | −$25.1M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -134.31 | -52.19 | -34.05 | -9.12 | -4.13 | -3.37 | -3.00 | -4.30 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $76M | $-2.14 | $-2.14–$-2.14 | 1 |
| 2027 | $99M | $6.14 | $6.14–$6.14 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CHEK.
No tracked institution reports a position in CHEK as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-11-25 | 1-for-20reverse |
| 2018-04-04 | 1-for-12reverse |
No one on the platform has traded CHEK yet.
| $433577 |
| — |
| HCWBHCW Biologics Inc. | $0.88 | -14.95% | $2M | — |
| LUCYInnovative Eyewear, Inc. | $0.82 | +4.75% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.